Loading…

Binding of cytokines to pharmaceutically prepared human immunoglobulin

Pharmaceutically prepared IgG, pooled from sera of over 2,000 normal individuals, contained both monomeric and dimeric IgG. Each type of IgG bound 125I-labeled interleukin (IL)-1 alpha, IL-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha. Increased binding to IgG was observed if 125I-IL-1 beta wa...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of clinical investigation 1993-11, Vol.92 (5), p.2533-2539
Main Authors: SVENSON, M, HANSEN, M. B, BENDTZEN, K
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c464t-5d82a70f78eab1708eba041a1ee6c6fb32af58586af51aee67631e76746b48543
cites
container_end_page 2539
container_issue 5
container_start_page 2533
container_title The Journal of clinical investigation
container_volume 92
creator SVENSON, M
HANSEN, M. B
BENDTZEN, K
description Pharmaceutically prepared IgG, pooled from sera of over 2,000 normal individuals, contained both monomeric and dimeric IgG. Each type of IgG bound 125I-labeled interleukin (IL)-1 alpha, IL-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha. Increased binding to IgG was observed if 125I-IL-1 beta was denatured by heating to 39 degrees C. However, the binding of both nondenatured and denatured 125I-IL-1 beta was not inhibited by unlabeled IL-1 beta. In contrast, binding of 125I-IL-1 alpha, 125I-IL-6, and 125I-TNF alpha was inhibited by the corresponding unlabeled cytokine. Papain-digestion of IgG abolished binding of 125I-TNF alpha but failed to influence the displaceable binding of 125I-IL-1 alpha and 125I-IL-6. 125I-TNF alpha was a mixture of trimeric and monomeric forms, the latter being the predominant form at lower concentrations. The apparent saturability of 125I-TNF alpha was explained by a higher nonspecific binding of monomeric than of trimeric 125I-TNF alpha to IgG. The amounts of cytokine antibodies in IgG preparations would contribute approximately 2 micrograms anti-IL-1 alpha IgG and 1 microgram anti-IL-6 IgG per kg body wt during high dose immune globulin therapy. In conclusion, pharmaceutical preparations of human IgG contain specific and neutralizing, high affinity antibodies against IL-1 alpha and IL-6, but not against TNF alpha or IL-1 beta. There are significant methodological pitfalls that hamper detection of IgG autoantibodies against cytokines.
doi_str_mv 10.1172/jci116862
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_288439</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76048630</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-5d82a70f78eab1708eba041a1ee6c6fb32af58586af51aee67631e76746b48543</originalsourceid><addsrcrecordid>eNpVkUtLxDAUhYMoOj4W_gChCxFcVPNqEhcudHB0RHCj63CbpjPRNqlJK8y_tzLDoKsD93z3wbkInRJ8RYik1x_GESKUoDtoQopC5YoytYsmGFOS30imDtBhSh8YE84Lvo_2FaWSCTFBs3vnK-cXWagzs-rDp_M2ZX3IuiXEFowdemegaVZZF20H0VbZcmjBZ65tBx8WTSiHxvljtFdDk-zJRo_Q--zhbfqUv7w-zqd3L7nhgvd5USkKEtdSWSiJxMqWgDkBYq0woi4ZhbpQhRKjEBiLUjBipZBclFwVnB2h2_XcbihbWxnr-wiN7qJrIa50AKf_O94t9SJ8a6oUZzdj_8WmP4avwaZety4Z2zTgbRiSlgJzJRgewcs1aGJIKdp6u4Ng_Zu5fp7O15mP7Nnfo7bkJuTRP9_4kMYs6wjeuLTFmGJ4_Ar7ATr5ivU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76048630</pqid></control><display><type>article</type><title>Binding of cytokines to pharmaceutically prepared human immunoglobulin</title><source>Free E-Journal (出版社公開部分のみ)</source><source>PubMed Central</source><creator>SVENSON, M ; HANSEN, M. B ; BENDTZEN, K</creator><creatorcontrib>SVENSON, M ; HANSEN, M. B ; BENDTZEN, K</creatorcontrib><description>Pharmaceutically prepared IgG, pooled from sera of over 2,000 normal individuals, contained both monomeric and dimeric IgG. Each type of IgG bound 125I-labeled interleukin (IL)-1 alpha, IL-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha. Increased binding to IgG was observed if 125I-IL-1 beta was denatured by heating to 39 degrees C. However, the binding of both nondenatured and denatured 125I-IL-1 beta was not inhibited by unlabeled IL-1 beta. In contrast, binding of 125I-IL-1 alpha, 125I-IL-6, and 125I-TNF alpha was inhibited by the corresponding unlabeled cytokine. Papain-digestion of IgG abolished binding of 125I-TNF alpha but failed to influence the displaceable binding of 125I-IL-1 alpha and 125I-IL-6. 125I-TNF alpha was a mixture of trimeric and monomeric forms, the latter being the predominant form at lower concentrations. The apparent saturability of 125I-TNF alpha was explained by a higher nonspecific binding of monomeric than of trimeric 125I-TNF alpha to IgG. The amounts of cytokine antibodies in IgG preparations would contribute approximately 2 micrograms anti-IL-1 alpha IgG and 1 microgram anti-IL-6 IgG per kg body wt during high dose immune globulin therapy. In conclusion, pharmaceutical preparations of human IgG contain specific and neutralizing, high affinity antibodies against IL-1 alpha and IL-6, but not against TNF alpha or IL-1 beta. There are significant methodological pitfalls that hamper detection of IgG autoantibodies against cytokines.</description><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/jci116862</identifier><identifier>PMID: 8227366</identifier><identifier>CODEN: JCINAO</identifier><language>eng</language><publisher>Ann Arbor, MI: American Society for Clinical Investigation</publisher><subject>Animals ; Antibodies - blood ; Biological and medical sciences ; Biological Products - immunology ; Cytokines - immunology ; Detergents - pharmacology ; Humans ; Immunoglobulin G - immunology ; Immunomodulators ; Interleukin-1 - immunology ; Interleukin-6 - immunology ; Medical sciences ; Milk ; Pharmacology. Drug treatments ; Tumor Necrosis Factor-alpha - immunology</subject><ispartof>The Journal of clinical investigation, 1993-11, Vol.92 (5), p.2533-2539</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-5d82a70f78eab1708eba041a1ee6c6fb32af58586af51aee67631e76746b48543</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC288439/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC288439/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3830454$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8227366$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SVENSON, M</creatorcontrib><creatorcontrib>HANSEN, M. B</creatorcontrib><creatorcontrib>BENDTZEN, K</creatorcontrib><title>Binding of cytokines to pharmaceutically prepared human immunoglobulin</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Pharmaceutically prepared IgG, pooled from sera of over 2,000 normal individuals, contained both monomeric and dimeric IgG. Each type of IgG bound 125I-labeled interleukin (IL)-1 alpha, IL-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha. Increased binding to IgG was observed if 125I-IL-1 beta was denatured by heating to 39 degrees C. However, the binding of both nondenatured and denatured 125I-IL-1 beta was not inhibited by unlabeled IL-1 beta. In contrast, binding of 125I-IL-1 alpha, 125I-IL-6, and 125I-TNF alpha was inhibited by the corresponding unlabeled cytokine. Papain-digestion of IgG abolished binding of 125I-TNF alpha but failed to influence the displaceable binding of 125I-IL-1 alpha and 125I-IL-6. 125I-TNF alpha was a mixture of trimeric and monomeric forms, the latter being the predominant form at lower concentrations. The apparent saturability of 125I-TNF alpha was explained by a higher nonspecific binding of monomeric than of trimeric 125I-TNF alpha to IgG. The amounts of cytokine antibodies in IgG preparations would contribute approximately 2 micrograms anti-IL-1 alpha IgG and 1 microgram anti-IL-6 IgG per kg body wt during high dose immune globulin therapy. In conclusion, pharmaceutical preparations of human IgG contain specific and neutralizing, high affinity antibodies against IL-1 alpha and IL-6, but not against TNF alpha or IL-1 beta. There are significant methodological pitfalls that hamper detection of IgG autoantibodies against cytokines.</description><subject>Animals</subject><subject>Antibodies - blood</subject><subject>Biological and medical sciences</subject><subject>Biological Products - immunology</subject><subject>Cytokines - immunology</subject><subject>Detergents - pharmacology</subject><subject>Humans</subject><subject>Immunoglobulin G - immunology</subject><subject>Immunomodulators</subject><subject>Interleukin-1 - immunology</subject><subject>Interleukin-6 - immunology</subject><subject>Medical sciences</subject><subject>Milk</subject><subject>Pharmacology. Drug treatments</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><recordid>eNpVkUtLxDAUhYMoOj4W_gChCxFcVPNqEhcudHB0RHCj63CbpjPRNqlJK8y_tzLDoKsD93z3wbkInRJ8RYik1x_GESKUoDtoQopC5YoytYsmGFOS30imDtBhSh8YE84Lvo_2FaWSCTFBs3vnK-cXWagzs-rDp_M2ZX3IuiXEFowdemegaVZZF20H0VbZcmjBZ65tBx8WTSiHxvljtFdDk-zJRo_Q--zhbfqUv7w-zqd3L7nhgvd5USkKEtdSWSiJxMqWgDkBYq0woi4ZhbpQhRKjEBiLUjBipZBclFwVnB2h2_XcbihbWxnr-wiN7qJrIa50AKf_O94t9SJ8a6oUZzdj_8WmP4avwaZety4Z2zTgbRiSlgJzJRgewcs1aGJIKdp6u4Ng_Zu5fp7O15mP7Nnfo7bkJuTRP9_4kMYs6wjeuLTFmGJ4_Ar7ATr5ivU</recordid><startdate>19931101</startdate><enddate>19931101</enddate><creator>SVENSON, M</creator><creator>HANSEN, M. B</creator><creator>BENDTZEN, K</creator><general>American Society for Clinical Investigation</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19931101</creationdate><title>Binding of cytokines to pharmaceutically prepared human immunoglobulin</title><author>SVENSON, M ; HANSEN, M. B ; BENDTZEN, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-5d82a70f78eab1708eba041a1ee6c6fb32af58586af51aee67631e76746b48543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Animals</topic><topic>Antibodies - blood</topic><topic>Biological and medical sciences</topic><topic>Biological Products - immunology</topic><topic>Cytokines - immunology</topic><topic>Detergents - pharmacology</topic><topic>Humans</topic><topic>Immunoglobulin G - immunology</topic><topic>Immunomodulators</topic><topic>Interleukin-1 - immunology</topic><topic>Interleukin-6 - immunology</topic><topic>Medical sciences</topic><topic>Milk</topic><topic>Pharmacology. Drug treatments</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SVENSON, M</creatorcontrib><creatorcontrib>HANSEN, M. B</creatorcontrib><creatorcontrib>BENDTZEN, K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SVENSON, M</au><au>HANSEN, M. B</au><au>BENDTZEN, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Binding of cytokines to pharmaceutically prepared human immunoglobulin</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>1993-11-01</date><risdate>1993</risdate><volume>92</volume><issue>5</issue><spage>2533</spage><epage>2539</epage><pages>2533-2539</pages><issn>0021-9738</issn><eissn>1558-8238</eissn><coden>JCINAO</coden><abstract>Pharmaceutically prepared IgG, pooled from sera of over 2,000 normal individuals, contained both monomeric and dimeric IgG. Each type of IgG bound 125I-labeled interleukin (IL)-1 alpha, IL-1 beta, IL-6, and tumor necrosis factor (TNF)-alpha. Increased binding to IgG was observed if 125I-IL-1 beta was denatured by heating to 39 degrees C. However, the binding of both nondenatured and denatured 125I-IL-1 beta was not inhibited by unlabeled IL-1 beta. In contrast, binding of 125I-IL-1 alpha, 125I-IL-6, and 125I-TNF alpha was inhibited by the corresponding unlabeled cytokine. Papain-digestion of IgG abolished binding of 125I-TNF alpha but failed to influence the displaceable binding of 125I-IL-1 alpha and 125I-IL-6. 125I-TNF alpha was a mixture of trimeric and monomeric forms, the latter being the predominant form at lower concentrations. The apparent saturability of 125I-TNF alpha was explained by a higher nonspecific binding of monomeric than of trimeric 125I-TNF alpha to IgG. The amounts of cytokine antibodies in IgG preparations would contribute approximately 2 micrograms anti-IL-1 alpha IgG and 1 microgram anti-IL-6 IgG per kg body wt during high dose immune globulin therapy. In conclusion, pharmaceutical preparations of human IgG contain specific and neutralizing, high affinity antibodies against IL-1 alpha and IL-6, but not against TNF alpha or IL-1 beta. There are significant methodological pitfalls that hamper detection of IgG autoantibodies against cytokines.</abstract><cop>Ann Arbor, MI</cop><pub>American Society for Clinical Investigation</pub><pmid>8227366</pmid><doi>10.1172/jci116862</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9738
ispartof The Journal of clinical investigation, 1993-11, Vol.92 (5), p.2533-2539
issn 0021-9738
1558-8238
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_288439
source Free E-Journal (出版社公開部分のみ); PubMed Central
subjects Animals
Antibodies - blood
Biological and medical sciences
Biological Products - immunology
Cytokines - immunology
Detergents - pharmacology
Humans
Immunoglobulin G - immunology
Immunomodulators
Interleukin-1 - immunology
Interleukin-6 - immunology
Medical sciences
Milk
Pharmacology. Drug treatments
Tumor Necrosis Factor-alpha - immunology
title Binding of cytokines to pharmaceutically prepared human immunoglobulin
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T01%3A03%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Binding%20of%20cytokines%20to%20pharmaceutically%20prepared%20human%20immunoglobulin&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=SVENSON,%20M&rft.date=1993-11-01&rft.volume=92&rft.issue=5&rft.spage=2533&rft.epage=2539&rft.pages=2533-2539&rft.issn=0021-9738&rft.eissn=1558-8238&rft.coden=JCINAO&rft_id=info:doi/10.1172/jci116862&rft_dat=%3Cproquest_pubme%3E76048630%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c464t-5d82a70f78eab1708eba041a1ee6c6fb32af58586af51aee67631e76746b48543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=76048630&rft_id=info:pmid/8227366&rfr_iscdi=true